SIGY
Sigyn Therapeutics, Inc.
$0.03
-0.01 (-23.08%)
At close · Jul 8
Market Cap
$48,161
Shares
1,605,377
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.04
Day$0.03–0.04
52W$0.01–5.00
Avg vol 30d21K
Short int16K · 1.0% float · 1.0d
Short vol67%
DataJan 2021–Jul 2026
Filing10-Q · Nov 14
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−97%
below
Price vs 50-day avg
−23%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−97%
trailing
YTD return
−98%
this year
Relative strength
−104%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.97% of float · ▼ -51.9% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Squeeze score
19
low risk · 0–100
Fundamentals
Revenue growth
+406%
Y/Y
Gross margin
75%
expanding
EPS growth
+33%
Y/Y
Free cash flow
$-873.3K
Balance sheet
$2.0M
net debt
Quant / Vol
risk profile
Volatility
295%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Nov 14, 2025
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−97%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.97% of float · ▼ -51.9% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $5
vs 200-day avg -97%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIGY
this stock
Sigyn Therapeutics, Inc.
|
$48,161 | -98.2% | +405.6% | — | 1.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIGY | -18.9% | -25.0% | -97.0% | -18.9% | -98.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -18.7% | -25.8% | -104.4% | -18.7% | -107.6% |